Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02983799
Recruitment Status : Recruiting
First Posted : December 6, 2016
Last Update Posted : November 21, 2018
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 21, 2020
  Estimated Study Completion Date : May 21, 2020